title: Should patient-rated performance status affect treatment decisions in advanced lung cancer?
abstract: BACKGROUND
  The Eastern Cooperative Oncology Group (ECOG) score is a well known prognostic factor and almost always used to determine eligibility for clinical trials. The patient-rated performance status score (Pt-PS), section of the patient generated subjective global assessment scale, has identical criteria to the physician-rated ECOG scale (MD-PS). We compared the Pt-PS with MD-PS in patients with advanced non-small cell lung cancer and compared the effect of each rating on eligibility for a hypothetical clinical trial.
  
  
  METHODS
  Consecutive patients with newly diagnosed advanced non-small cell lung cancer completed a patient generated subjective global assessment self-rated questionnaire, which was then correlated (kappa statistic) with the ECOG PS recorded at the same time. Patients were treated with standard chemotherapy. Survival was determined using Kaplan-Meier statistics.
  
  
  RESULTS
  One hundred nine patients (M:F-54:55) were recruited. Pt-PS differed from MD-PS in 59 (54%) instances (p = 0.0001). When scores were not congruent, 41/59 (69%) patients evaluated themselves as having a worse PS than the physician's rating. Pt-PS was 0 to 1 in 60 (55%) patients whereas MD-PS was 0 to 1 in 78 (72%) patients. The functional status irrespective of evaluator was predictive of survival (p = 0.001 for MD-PS and p = 0.001 for Pt-PS). However, the median survival in those with MD-PS >/=2 was 3.3 (CI; 1.7-4.9) months whereas individuals with Pt-PS >/=2 had a median survival of 6.2 (CI; 5.4-6.9) months.
  
  
  CONCLUSIONS
  Pt-PS and MD-PS were not congruent in over half of the cases, with Pt-PS scores usually poorer. Almost half the patients would have excluded themselves from a hypothetical clinical trial (Pt-PS >/=2). This requires prospective evaluation.
authors.affiliation: Department of Medicine, Division of Pulmonary Diseases, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada. edajczma@pne.jgh.mcgill.ca
authors.forename: Esther
authors.initials: E
authors.lastname: Dajczman
authors.forename: Goulnar
authors.initials: G
authors.lastname: Kasymjanova
authors.forename: Harvey
authors.initials: H
authors.lastname: Kreisman
authors.forename: Nelda
authors.initials: N
authors.lastname: Swinton
authors.forename: Carmela
authors.initials: C
authors.lastname: Pepe
authors.forename: David
authors.initials: D
authors.lastname: Small
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003657:Decision Making; D004608:Eligibility Determination; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status / Q000592:standards*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D010817:Physician-Patient Relations; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D011795:Surveys and Questionnaires; D015996:Survival Rate